June 30, 2020
Multidistrict Litigation 101: The What, How And Why Of Pursuing Justice For Serious Injury
July 16, 2020
Show all

ZANTAC: A Dangerous Drug

You are probably familiar with the popular heartburn medication Zantac, made from the generic drug ranitidine. This drug is mostly sold over the counter but is also available through a prescription for more serious related illnesses such as ulcers. Zantac has been found to contain high levels of N-nitrosodimethylamine (NDMA) – a substance classified as a probable human carcinogen.

Are you a long-time user of Zantac? Have you been diagnosed with cancer of the liver, stomach, pancreas, kidney, bladder or any other vital organ? If so, you could be entitled to significant compensation for this egregious injury.

There is existing mass tort litigation related to these serious injuries caused by Zantac. And KR Law is a mass tort law firm.

In Re: Zantac (Ranitidine) Products Liability Litigation is an active multidistrict litigation centralized in the Southern District of Florida. You may be eligible to join this MDL as one of tens of thousands of plaintiffs nationwide.

The attorneys at KR Law have a long, prolific history of winning mass torts for our clients. We have decades of experience navigating and managing pharmaceutical-related MDLs, which can be complex and challenging.

Our attorneys can help you:

  • Fight the giant drug makers behind Zantac’s creation and popularity
  • Fight scores of generic drug manufacturers that produce, distribute and sell ranitidine.
  • Maximize the damages you receive to compensate you for your injury, loss of income, pain and suffering and other consequence

Tell me more about NDMA.

How did Zantac become contaminated with NDMA, a common ingredient in rocket fuel? It turns out the problem was not a matter of accidental contamination. The truth is that ranitidine breaks down into NDMA when metabolized. In other words, the drug itself is the contaminant. It is actually impossible to have uncontaminated ranitidine. This is disconcerting, considering the Environmental Protection Agency has declared the substance a probable human carcinogen. Prolonged exposure only increases the chances of developing cancer, something testing on animals has proven.

How bad is the contamination? A clinical study conducted at Stanford University in 2016 showed that research subjects demonstrated the level of NDMA found in their urine 24 hours after consuming Zantac increased by 430 times the level found 24 hours before this ingestion. That alarmingly high level rated 495 times higher than the daily limit prescribed by the Food and Drug Administration (FDA). In other studies, the NDMA level found in patients’ urine has proven to be 15,000 times higher than the allowable limit in California’s drinking water.

How has the FDA responded to this issue?

Despite these facts, the FDA never forced a recall. Rather, the agency issued a warning. Several manufacturers and drug stores suspended the sale of ranitidine products.

However, all drug recalls are voluntary. No matter how dangerous a drug might be, the FDA will not force a recall.

Where does that leave me?

If the federal government will not properly address this issue, then we will. We use the courts, the legal process and our society’s desire to make the serious injury victims whole as our weapons.

Big Pharma has deep pockets, but we have the expertise and a track record of success. We are not afraid to take on big fights and push back against the greedy pharmaceutical company that caused you harm.

Are you ready to pursue justice and get financially compensated for your injuries caused by Zantac? Contact us today for a free case evaluation.

Kristian Rasmussen
Kristian Rasmussen
Kristian Rasmussen has been appointed by United States District Judge Inga Johnson as a lead attorney serving on the Plaintiffs Steering Committee for MDL No. 2092, In Re Chantix (varenicline) Products Liability Litigation. Mr. Rasmussen’s prior litigation experience includes being designated as Co-Lead Trial Counsel for MDL No. 1632, In re High Sulfur Content Gasoline Products Liability Litigation and being appointed by United States District Judge Charles Bryer to serve as a lead attorney on the Plaintiffs Steering Committee as co-chair of the discovery committee for MDL No. 1699, In Re Bextra and Celebrex Unfair Sales Practices and Product Liability Litigation. Additionally, before entering into private practice, Mr. Rasmussen prosecuted cases as a Special Assistant United States Attorney in the Northern District of Florida and served the United States Navy as an officer in the Judge Advocate General’s Corps. Mr. Rasmussen has been awarded multiple verdicts and settlements in excess of One Million Dollars.

Comments are closed.